SAN FRANCISCO, CA–(Marketwired – December 15, 2016) – 3D Signatures Inc. (TSX VENTURE: DXD), a Canadian company developing a platform of “disruptive” personalized prognostic tests for patients with 13 different cancers and Alzheimer’s disease, has attracted the attention of several stock watchers with its most recent announcements.

Included in this article is: 3D Signatures Inc.

The 3D Signatures platform combines minimally invasive blood tests with software that uses three-dimensional imagery of a patient’s chromosomes to determine the stage of disease and zero in on the best treatment for that individual.

By combining a “biotech play with a software and technology play” to generate a profile of a patient’s disease, physicians are able to customize treatment plans to the individual, company CEO Jason Flowerday explained in an interview, adding the 3D Signatures technology also could provide savings for payers by avoiding the costly administration of treatments that would not be effective.

Continue reading this article: Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth

About Streetwise Reports — The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

3D Signatures Inc. is a billboard sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

Please see the end of the article for the complete disclosure: Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth

Contract Information:
Carrie Beal Amaro
Associate Publisher
Email contact